

Special Issue

Genomic Insights and Translational Opportunities for Human Cancers

Message from the Guest Editors

The field of cancer genomics has undergone a revolution in recent years with the advent of next-generation sequencing technologies and the development of new algorithms that can analyze large amounts of genomic information. These advances have enabled researchers to sequence cancer genomes with unprecedented accuracy, leading to new insights into the genetic basis of cancer, and opening up new avenues for cancer diagnosis, treatment, and prevention. By understanding the specific genetic mutations and transcriptomic changes that are present in a particular cancer, scientists can also develop more targeted and effective therapies. This Special Issue on genomic insights into human cancer focuses on the latest advances in cancer genomics, with an emphasis on the translational potential of these findings. The articles in this Special Issue will cover recent advances in cancer genomics, including: i) advances in bioinformatics algorithms, such as machine learning and artificial intelligence, and their application in cancer research; ii) novel cancer biomarkers, particularly those pertaining to liquid biopsies; and iii) other translational research relating to cancer.

Guest Editors

Prof. Dr. Apostolos Zaravinos

Cancer Genetics, Genomics and Systems Biology Laboratory, Basic and Translational Cancer Research Center (BTCRC), Nicosia 1516, Cyprus

Dr. Ilias Georgakopoulos-Soares

Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA 17033-0850, USA

Deadline for manuscript submissions

closed (31 May 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/185423

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).